These findings demonstrate that NP1192, when combinedwith anti-PD-L1 blockade, enhances the CD8+ Teff cell population, reprograms the TME, and potentiates antitumor immunity,suggesting its potential for clinical application in cancer immunotherapy. The gene discussed is CD8A; the disease is cancer.